

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,  
and Philippe Valadon  
Serial No.: 08/833,838  
Filed: April 10, 1997  
Page 6

as required by the Sequence Rules, and to add the Sequence Listing. The amendments to the specification are supported by the application as originally filed. Accordingly, entry of the amendments to the specification is respectfully requested.

By this Amendment, applicants also have amended Claims 54-66 and 71-74 to refer to the correct sequence identifiers. The amendments to Claims 54-66 and 71-74 are supported by the application as originally filed, and do not introduce new material. Accordingly, entry of the amendments to Claims 54-66 and 71-74 is respectfully requested.

In view of the preceding amendments and the remarks which follow, applicants respectfully request that the Examiner reconsider and withdraw the rejections set forth in the February 7, 2001 Office Action, and earnestly solicit allowance of the claims currently under examination, namely, Claims 54-74.

35 U.S.C. §102(a) Rejections

Claims 54 and 63-74 were rejected under 35 U.S.C. §102(a) as being anticipated by Gaynor *et al.*, "Peptide inhibition of glomerular deposition of an anti-DNA antibody", which was published in vol. 94 of *Proc. Nat. Acad. Sci. USA*, at pages 1955-60, in March 1997 (the "Gaynor *et al.* article"). In addition, Claims 54, 63-66, and 71-74 were rejected under 35 U.S.C. §102(a) as being anticipated by Spatz *et al.*, "Studies on the structure, regulation, and pathogenic potential of anti-dsDNA antibodies", which was published in vol. 11(1) of *Methods*, at pages 70-78, in January 1997 (the "Spatz *et al.* article").

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,  
and Philippe Valadon  
Serial No.: 08/833,838  
Filed: April 10, 1997  
Page 7

In response to the rejections, applicants enclose herewith, as Exhibit A, an executed Declaration of the Inventors (four copies). The Declaration of the Inventors establishes that, even though Chaim Puttermann and Linda Spatz were identified with the applicants as co-authors of the Gaynor *et al.* article, they did not contribute to the conception of the invention described and claimed in the subject application.

The Declaration of the Inventors further establishes that, even though Linda Spatz, Andrey Iliev, Vladimir Saenko, Lori Jones, Macarena Irigoyen, Audrey Manheimer-Lory, Chaim Puttermann, Margaret Bynoe, Czeslawa Kowal, Philip Kuo, and Jeffrey Newman were identified with the applicants as co-authors of the Spatz *et al.* article, they did not contribute to the conception of the invention described and claimed in the subject application.

Since the Gaynor *et al.* article and the Spatz *et al.* article were the inventors' own publications, and were published within one year of the April 10, 1997 filing date of the subject application, applicants respectfully submit that the Gaynor *et al.* article and the Spatz *et al.* article are not prior art under §102(a). Accordingly, applicants respectfully request that the Examiner withdraw the rejections set forth in the February 7, 2001 Office Action, and earnestly solicit allowance of the claims currently under examination.

#### Compliance with Sequence Rules

In the February 7, 2001 Office Action, the Examiner indicated that the subject application failed to comply with the Sequence Rules. In response thereto, applicants attach herewith Exhibit B, consisting of pages 1-9 of the Sequence Listing.

Applicants: Bruce D. Gaynor, Betty A. Diamond, Matthew D. Scharff,  
and Philippe Valadon  
Serial No.: 08/833,838  
Filed: April 10, 1997  
Page 8


Also enclosed is a computer-readable form containing the Sequence Listing (Exhibit C). Additionally, the specification has been amended to contain the correct sequence identifiers, as required by the Sequence Rules.

The undersigned attorney hereby certifies that the information recorded in computer-readable form is identical to the written Sequence Listing, is supported by the application as filed, and does not introduce new matter into the application as filed. In view of the above-noted amendments and these remarks, applicants respectfully submit that they have complied with the Sequence Rules. Accordingly, entry of the Sequence Listing is respectfully requested.

No fee, other than the \$195.00 fee for a two-month extension of time, is deemed necessary in connection with the filing of this Amendment. If any additional fee is required to preserve the pendency of the subject application, authorization is hereby given to charge any such additional fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

By:   
Craig J. Arnold  
Registration No. 34,287

Dated: July 9, 2001  
New York, NY

SCHEDULE AREDLINED VERSIONIn the Specification:

Please replace the paragraph at page 4, line 1 as follows:

Figure 3 depicts peptide inhibition of R4A (1 µg/ml) binding to calf thymus double stranded DNA by Enzyme Linked ImmunoSorbent Assay. ◊ = Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2)

In the Claims:

Please rewrite Claims 54-66 and 71-74 as follows:

54. (amended) A method for treating glomerulonephritis mediated by anti-double stranded (ds)-DNA antibodies in a subject in need of such treatment comprising administering to said subject at least one peptide which binds an anti-double stranded DNA antibody in an amount effective to treat glomerulonephritis, wherein said peptide comprises an amino acid sequence of (i) X-Gly-Trp-X-Arg-Val (SEQ ID NO:3 2), wherein X represents any amino acid known in the art; (ii) X-Trp-X-Tyr-His-X (SEQ ID NO:4 3), wherein X represents any amino acid known in the art; (iii) X1-Trp-X1-Tyr-X2 (SEQ ID NO:2 4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser; or (iv) X1-Gly-X1-Trp-Pro-Arg (SEQ ID NO:5), wherein X1 represents Asp or Glu.

55. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:3 2), wherein X represents any amino acid known in the art.

56. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:~~3~~ 2), wherein X represents any amino acid known in the art.

57. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X-Gly-Trp-X-Arg-Val (SEQ ID NO:~~3~~ 2), wherein X represents any amino acid known in the art.

58. (amended) The method according to Claim 54 wherein said peptide consists of X-Gly-Trp-X-Arg-Val (SEQ ID NO:~~3~~ 2), wherein X represents any amino acid known in the art.

59. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:~~4~~ 3), wherein X represents any amino acid known in the art.

60. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:~~4~~ 3), wherein X represents any amino acid known in the art.

61. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X-Trp-X-Tyr-His-X (SEQ ID NO:~~4~~ 3), wherein X represents any amino acid known in the art.

62. (amended) The method according to Claim 54 wherein said peptide consists of X-Trp-X-Tyr-His-X (SEQ ID NO:~~4~~ 3), wherein X represents any amino acid known in the art.

63. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2 4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

64. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2 4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

65. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises X1-Trp-X1-Tyr-X2 (SEQ ID NO:2 4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

66. (amended) The method according to Claim 54 wherein said peptide consists of X1-Trp-X1-Tyr-X2 (SEQ ID NO:2 4), wherein X1 represents Asp or Glu, and X2 represents Gly or Ser.

71. (amended) The method according to Claim 54 wherein said peptide is 5-30 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2 4).

72. (amended) The method according to Claim 54 wherein said peptide is 5-15 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2 4).

73. (amended) The method according to Claim 54 wherein said peptide is 5-10 amino acids in length and comprises d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2 4).

74. (amended) The method according to Claim 54 wherein said peptide consists of d-Asp-Trp-Glu-Tyr-Ser (SEQ ID NO:2 4).